Loading...
•
Aug 31, 2021
Nurix Q3 2021 Earnings Report
Nurix reported financial results for the third quarter ended August 31, 2021 and provided a corporate update.
Key Takeaways
Nurix Therapeutics reported collaboration revenue of $10.3 million and a net loss of $28.8 million, or ($0.65) per share for the third quarter ended August 31, 2021. The company's cash, cash equivalents and investments totaled $465.4 million as of August 31, 2021.
Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer
Expanded Board of Directors with experienced business leaders
Collaboration revenue increased due to the continued scale up of internal resources and external spending for collaborations with Sanofi and Gilead
Cash position remains strong with $465.4 million as of August 31, 2021
Revenue by Segment
Forward Guidance
The remainder of 2021 promises to be an exciting time for Nurix as they prepare to deliver on their ambitious goal of initiating Phase 1 trials for two additional wholly owned and internally developed drug candidates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...